- Merus N.V. (MRUS, Financial) will present updated interim clinical data at the 2025 ASCO® Annual Meeting.
- The phase 2 trial data for petosemtamab with pembrolizumab shows substantial clinical activity for PD-L1+ HNSCC treatment.
- An investor conference call is scheduled for May 22, 2025, to discuss the complete dataset.
Merus N.V. (MRUS) has announced the acceptance of their abstract for presentation at the 2025 ASCO® Annual Meeting to be held in Chicago. The presentation, scheduled for June 2, 2025, will feature updated interim clinical data from a phase 2 trial of petosemtamab combined with pembrolizumab as a first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This poster presentation will build upon data revealed at ASCO 2024, covering the complete dataset of 45 patients.
According to Merus CEO, Bill Lundberg, petosemtamab is showing potential as a first and best-in-class treatment, with significant clinical activity demonstrated across key metrics such as overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). These improvements surpass historical controls, offering promising outcomes both in the general population and in subgroups defined by HPV status and PD-L1 expression levels.
Merus will conduct an investor conference call on May 22, 2025, at 5:30 p.m. ET to discuss the full dataset. Investors and stakeholders can access the live webcast through the company's website. The complete dataset will provide further insights into petosemtamab's efficacy and its potential to redefine standard care practices for patients with aggressive forms of HNSCC.
The phase 3 LiGeR-HN1 trial, which evaluates petosemtamab's combination with pembrolizumab against pembrolizumab monotherapy, is set to enroll approximately 500 patients. This advancement underscores the company's commitment to addressing significant unmet medical needs in the treatment of head and neck cancer.
